OBJECTIVES: Typical carcinoids (TCs) are rare, slow-growing neoplasms, usually characterized by satisfactory surgical outcomes. Due to the rarity of TCs, international guidelines for the management of particular clinical presentations currently do not exist. In particular, nonanatomical resections (wedges) are sometimes advocated for Stage 1 TCs because of their indolent behaviour. The aim of this paper was to evaluate the most effective type of surgery for Stage 1 TCs, using the European Society of Thoracic Surgeons retrospective database of the Neuroendocrine Tumors of the Lung Working Group.
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METHODS:
We analysed the effect of surgical procedure on the survival of patients with Stage 1 TCs. Overall survival (OS) was calculated from the date of intervention. The cumulative incidence of cause-specific death (tumour-and non-tumour-related) was also estimated. The impact of the surgical procedure (i.e. lobectomy vs segmentectomy vs wedge resection) on survival was investigated using the Cox model with shared frailty (for OS, accounting for the within-centre correlation) and the Fine and Gray model (for cause-specific mortality) using the approach based on the multinomial propensity score. Effects were estimated including in the model the logit-transformed propensity scores of segmentectomy and wedge resection as covariates.
RESULTS:
A total of 876 patients with Stage 1 TCs (569 women, 65%) were included in this study. The median age was 60 years (interquartile range 47-69). At the last follow-up, 66 patients had died: The 5-year OS rate was 94.3% [95% confidence interval (CI) 92.2-95.9]. The 5-year cumulative incidences of tumour-and non-tumour-related deaths were 2.4% (95% CI 1.4-3.9) and 3.9% (95% CI 2.5-5.6%),
INTRODUCTION
Bronchial carcinoids (BCs) belong to the family of lung neuroendocrine tumours [1] , which also includes more biologically aggressive neoplasms (large-cell neuroendocrine carcinomas and small-cell carcinomas). BCs are rare tumours with an annual incidence that may range between 2.3 and 2.8 cases per 1 million people [2] ; they also represent 20-25% of all carcinoid tumours but account for only 0.4-3% of all primary lung cancers. An increase in prevalence over the last 30 years (6% per year) has been observed, regardless of confounding demographic factors such as age, gender and race [3] . This tendency of BCs to increase over time is probably due to improved awareness and increased use of special immunohistochemical stains. Nearly 90% of BCs are typical carcinoids (TCs) [4] , characterized by a uniquely favourable prognosis, with 85-90% 10-year survival after surgery [5] . Despite the satisfactory outcome with TCs, the optimal extent of surgical resection is still controversial, especially for Stage 1 TCs. In particular, non-anatomical (wedge) resections have been advocated, especially for peripheral small tumours, because of the indolent biological behaviour of TCs. Moreover, due to the rarity of the tumours, large randomized controlled trials with sufficient statistical power are unlikely to be organized.
In 2012, the European Society of Thoracic Surgeons (ESTS) created the Neuroendocrine Tumors of the Lung Working Group (NETs-WG), with the aim of gathering a group of experts worldwide, developing knowledge about such rare neoplasms and disseminating it in the scientific community. A dedicated database was designed, and a retrospective collection of patients was started. More than 2000 patients who have been operated on for neuroendocrine tumours were collected from several European and American institutions through 31 January 2014.
The aim of this paper was to answer the question as to which is the most appropriate surgical resection in patients with Stage 1 TCs.
PATIENTS AND METHODS
This study was a retrospective, multicentre cohort investigation of patients operated on for Stage 1 TCs between 1994 and 2012. Records were acquired from the ESTS NETs-WG retrospective database, as previously described [6, 7] .
The 'tumour location' was defined as follows: tumours directly visualized through bronchoscopy, associated with lung atelectasis or with obstructive pneumonia were classified as 'central', whereas those lesions not seen at bronchoscopy were classified as 'peripheral'.
The surgical procedures considered in this study were wedge resection, segmentectomy, lobectomy and bronchoplastic procedures (i.e. sleeve lobectomy). The latter were included in the lobectomy group. Patients receiving a pneumonectomy were excluded from the final analysis. Lymph node dissection data were also collected: Lymphadenectomy was classified as 'sampling' or 'systematic hilar and mediastinal'.
Histological specimens were reassessed by local pathologists. The definitive histological diagnosis of the TCs was based on the 2004 World Health Organization Lung Tumors Classification [1] and on Travis' histological guidelines for the diagnosis of lung neuroendocrine tumours [8] . Tumour staging was classified according to the 7th tumour, node and metastasis (TNM) staging system for malignant lung tumours [9] .
Statistical analysis
Continuous data are presented as median (interquartile range) and categorical data as frequency with percentage.
Patient characteristics were compared according to the type of surgery using the Kruskal-Wallis test for continuous variables and by the v 2 or Fisher exact tests when the expected frequency in any cell was <5.
Overall survival (OS) was calculated starting from the date of intervention to the date of death from any cause or the date of the last follow-up visit. OS function was estimated by the KaplanMeier product-limit method. Cumulative incidence of causespecific mortality (tumour-and non-tumour-related) was also estimated using the method proposed by Gooley et al. [10] .
The impact of the surgical procedure (i.e. lobectomy vs segmentectomy vs wedge resection) on OS was investigated using the Cox model with shared frailty (accounting for the withincentre correlation); the comparisons were adjusted using the approach based on the multinomial propensity score (PS) proposed by Spreeuwenberg et al. [11] . We divided the patients into 3 groups: the first group included patients who had lobectomies and sleeve lobectomies; the second group, wedges; and the third group, segmentectomies. For each patient, we calculated the PSs for the likelihood of receiving a specific treatment using a multinomial logistic regression model from 10 covariates, including age, gender, smoking habit, tumour location, previous malignancy, Eastern Cooperative Oncology Group Performance Status, tumour size, stage and vascular invasion. The comparisons between groups were performed using the Cox models with shared frailty and the Fine and Gray model [12] for OS and causespecific death, respectively. Effects were estimated by including in the model the logit-transformed PSs of segmentectomy and wedge resection as covariates. For all estimated models, missing data were handled by multiple imputation, and combined estimates were obtained from 5 imputed data sets. The statistical analysis was performed using STATA (version 13.2, StataCorp LP, College Station, TX, USA).
RESULTS

Patients' clinical characteristics
According to the selection criteria, 876 patients with Stage 1 TCs were included in the final analysis. The clinical and pathological characteristics of the patients are shown in Table 1 . The median age at surgery was 60 years (interquartile range 47-69). The majority of patients were women (569, 65%) and never-smokers (475, 54%). Previous malignancies were observed in 160 cases (18%). A peripheral tumour was detected in 249 patients (43%).
Surgical treatment
The types of surgical interventions are also illustrated in Table 1 . Lobectomy was the most common operation performed (616, 70%), followed by wedge resection (122, 14%), segmentectomy (75, 9%) and sleeve lobectomy (63, 8%).
Patients who had wedge resections were more likely older (P < 0.001), women (P = 0.046), with a peripheral lesion (P < 0.001) and with a history of previous malignancy (P < 0.001). Patients' Eastern Cooperative Oncology Group Performance Status, smoking habits and presence of tumoural vascular invasion were not dissimilar among the groups.
Survival analysis
At the last follow-up, 66 patients (7%) had died (16 tumourrelated, 50 non-tumour-related). The 5-year OS rate was 94% [95% confidence interval (CI) 92.2-95.9]. The 5-year cumulative incidences of tumour-and non-tumour-related deaths were 2.4% (95% CI 1.4-3.9%) and 3.9% (95% CI 2.5-5.6%), respectively.
Wedge resection showed a lower OS (5-year OS 82%, 95% CI 0.71-0.89; P < 0.001) compared to other anatomical resections (lobectomy 5-year OS 96%, 95% CI 0.94-0.99; segmentectomy 5-year OS 94%, 95% CI 0.84-0.98) (Fig. 1) . The same trends were detectable for the cumulative incidence of cause-specific deaths (Figs 2 and 3) .
The analysis performed using the multinomial PS approach confirmed the significantly worse survival of patients treated with a wedge resection compared to those who received a lobectomy (hazard ratio 2.01, 95% CI 1.09-3.69; P = 0.024) ( Table 2 ). Similar effects of wedge resection were also observed on cause-specific mortality: tumour-related (hazard ratio 2.28, 95% CI 0.86-6.02; P = 0.096); non-tumour related (hazard ratio 1.74, 95% CI 0.89-3.40; P = 0.105).
DISCUSSION
Surgery is recognized as the mainstay for the treatment of BCs, and operative strategy may vary according to their histology: Lung-sparing operations are usually reserved for TCs, whereas lobectomy/pneumonectomy is used for atypical carcinoids. Nevertheless, the optimal surgical management, especially for clinical Stage 1 tumours, is still a matter of discussion. Evidence favouring a sublobar versus a formal anatomical resection has been reported occasionally, commonly based on retrospective series, sometimes pooled from cooperating institutions, spanning several decades, without strong statistical power, able to detect a clinically relevant survival advantage between the 2 surgical approaches. A randomized clinical trial is really the only tool capable of providing the answer to this question, but it is almost impossible due to the rarity of BCs.
Some authors have relied on the Surveillance Epidemiology End Results to collect a large retrospective series of patients and therefore to draw some clinical conclusions [13, 14] . Nevertheless, the Surveillance Epidemiology End Results database has several significant intrinsic limitations because it does not provide detailed information concerning important clinical covariates (e.g. smoking history, comorbidities, type and completeness of resection, recurrence development), which may seriously limit the interpretation of the results.
The present study was based on the ESTS NETs-WG retrospective international database. We intentionally focused on the management and outcome of Stage 1 TCs. We deliberately did not consider atypical carcinoids because of their different biological behaviour, which justifies a more aggressive surgical approach, similar to that with other primary lung tumours [15, 16] .
Moreover, we were able to differentiate the sublobar resection group into wedge resection and segmentectomy and therefore to consider them separately. The same method was not possible for many other authors who investigated the role of surgical approaches in the outcome of BCs before we did [13, 14] .
The results of our study supported the adoption of anatomical resections for the treatment of Stage 1 TCs. Indeed, wedge resection was associated with significantly reduced survival. As previously reported [17, 18] , patients receiving wedge resections were significantly older, with a peripherally located lesion and with a history of a previous malignancy. Clinical comorbidities along with the peripheral location of the tumour may have influenced the choice of a wedge resection. Similarly, the recent European Neuroendocrine Tumour Society guidelines on the management of BCs [19] reported that sublobar wedge resections have been performed routinely in patients with limited pulmonary function or with severe comorbidities. Nevertheless, in a recent survey of the ESTS members, a minimum percentage of the responders (11%) regarded wedge resection as an oncologically adequate surgical procedure [20] . Rea et al. [21] , in a large retrospective single-centre series of 252 patients, showed that, on univariate analysis, the type of surgery was a significant prognostic factor (lobectomy 10-year OS 84.6%; pneumonectomy 10-year OS 60%; and segmentectomy/ wedge resection 10-year OS 80.8%, P = 0.003). Ferguson et al. [22] reported the same result, albeit without statistical significance, (survival: lobectomy 86% at 5 years; wedge resection 82% at 5 years), whereas Yendamuri et al. [13] , Bini et al. [23] and Chen et al. [24] concluded that the extent of surgical resection did not predict survival in patients with BCs. Therefore, they concluded that wedge resection, without compromising the oncological principles of margin adequacy, might be considered a reasonable alternative to a more extensive surgical lung resection for small peripheral lesions. One of the major limitation of these studies was that the authors grouped wedge and segmental resections together, which is not correct from an oncological point of view. Indeed, segmentectomy is considered an anatomical resection and an adequate treatment for primary lung cancers, whereas wedge resection is not.
Despite their indolent biological behaviour, TCs are currently considered malignant tumours [25, 26] , because they may be locally aggressive, and lymph nodal involvement, distant metastases, and tumour recurrences may also be observed. Moreover, a recent study reports nearly 10% N2 positivity in resected TCs when a systematic node dissection has been performed [27] . It is obvious that lymph node dissection should be regularly done in this disease. It may therefore be difficult for a surgeon to justify a wedge resection alone as a radical oncological procedure, given the risk of missing possible N1 nodes located between the site of the wedge resection and the dissected mediastinal lymph nodes.
To the best of our knowledge, this is the first study that demonstrates a significantly better survival and tumour-related survival rate with anatomic resections in a large series of Stage 1 TCs.
It is well known that lobectomy remains the most reliable surgical treatment for early-stage non-small-cell lung cancer in young patients with adequate pulmonary reserve and good cardiac function [28] . This recommendation was based mainly on the results of large multicentre studies [29, 30] . The locoregional recurrence rate in the group who had sublobar resections was reported to be 300% higher than that in the lobectomy group; in addition, the annual death rate was 30% lower in the latter group. Therefore, wedge resections have been reserved for high-risk patients who generally are unable to tolerate a lobectomy because of significant impairment in cardiopulmonary reserve.
Whereas centrally located TCs (Fig. 2 ) are usually treated with lobectomy or sleeve resection, small peripheral lesions are often treated with a wedge resection. We demonstrated that, in such patients, segmentectomy should be preferred to wedge resection for a more oncologically adequate treatment of the tumour.
Limitations
Our study has some potential limitations, represented by the retrospective design, the lack of a centralized histological review process and the relatively low median follow-up time.
CONCLUSION
In conclusion, this retrospective multicentre analysis of a large database of resected TCs showed that the extent of surgical resection represents an important predictor for survival in patients with Stage 1 TCs. We concluded that even with small peripheral tumours, an anatomical resection is the most appropriate treatment, improving patient survival. Furthermore, these results should be taken into account in future clinical guidelines for the management of TCs.
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APPENDIX. CONFERENCE DISCUSSION
Dr K. Papagiannopoulos (Leeds, UK): This is a cohort of patients that spans 20 years, with a very large number of resections. How confident are you yourself that people have reported appropriately histology, even before 2004 classification. In extension to that, I haven't seen much discussion in the draft about the lymphadenectomy that patients had, so whether it was sampling or whether it was a complete lymphadenectomy. My second question is, you produced a significant, elegant study in 2015 in which you have produced a risk model for overall survival and the factors that you had in there was: male preponderance, age, people that have second or previous cancers and peripheral tumours as well. If we look at this group of people with peripheral tumours, they had at least 3 or 4 of those variables. Was it truly the extend of resection that had an impact on overall survival or was it simply the same group of patients with genetic predisposition to disease and we just happen to find that group of people again. My third question is, how confident are you after this study to essentially advise the audience that all patients with typical carcinoids, regardless of whether they're young, should have an anatomical resection and what should that be, a segmentectomy or a classic lobectomy. Dr P.L. Filosso (Torino, Italy): Thank you very much for your comments and questions. First, you mentioned the problem of histology. As I reported before, during my presentation, this is a retrospective and multicentre study, which may suffer of possible limitations, one of which is the lack of histopathological review process. However, two points have to be considered concerning this issue. First, all the specimens are locally reviewed by pathologists expert in neuroendocrine tumour and second, more important, the diagnosis of typical carcinoid was done according to the Travis' strict histological criteria, widely accepted by the scientific community of pathologists. Furthermore, the fact that overall survival curve of our populations is quite similar to other observed in the literature makes us confident to consider all the patients really affected by a typical carcinoid.
The second question is also very important, since in our retrospective database can observe, in some cases, a lack of information on the extent of lymphadenectomy. We know if the surgeon has performed sampling or extended lymphadenectomy but we don't know the number and lymph node stations resected. But I'm confident that the new prospective database, which is now available online and through which up till now we collected more than 170 new cases, will give a definitive answer to your question.
Concerning your last question, I think that since overall survival curve and hazard ratio for the survival after segmental resection and lobectomy are quite similar in this study, we could accept that in peripheral nodules a segmental resection is indicated, but taking into account the oncological criteria of marginfree and correct lymphadenectomy.
Dr F. Detterbeck (Connecticut, USA): Much of what we have thought in the past was really a slightly educated guess but not really based on data, so this is wonderful. I am struck however by several aspects of the survival curve of the patients that had wedge resection. The survival is worse than what we have typically seen, even for node positive typical carcinoid patients, so that makes me worried that it is really due to other causes of death. As I understood this, these were both central and peripheral typical carcinoid patients. Certainly we see peripheral carcinoids more commonly in older patients and I suspect that patients with comorbidities were also probably more likely to have a wedge resection. The eShape of that survival curve makes me wonder if this isn't just age-related phenomenon that makes it go down more steeply and this is not related to death from carcinoid tumours, in which case we are drawing the wrong conclusion. I would just say that any multivariate or propensity score analysis is only as good as the variables that you are able to put into that, and if you are not able to put comorbidities into it, then that still remains a big, open question. The propensity or multivariate score is not magical, it depends on what data you have available to be able to be able to really dig down and understand.
Dr Filosso: As I mentioned before during my presentation, patients who received wedge resection were older and had some comorbidities. However, I have also to mention that comorbidities have been included in the propensity score adjust model and I think that curves really represent a sort of trend of worse prognosis for patients who received a wedge. However, I think that this issue will be finally demonstrated by the prospective database, the results of which are awaited in few years.
Dr B. Naidu (Birmingham, UK): Just to reiterate the importance of the cause of death here as being a real limitation to this study, but perhaps a point that you have made earlier on may push it towards anatomical resection. You have mentioned the diagnosis of atypical versus typical as a postoperative diagnosis. In your decision making, intraoperatively, that may play role in whether you choose to do anatomical resection. I don't know if you have got any thoughts on that.
Dr Filosso: Also frozen section would not be able to differentiate a typical from an atypical carcinoid. Therefore this situation should guide your type of resection, and this is why I stress the idea of anatomical resection even in case of typical carcinoid. The philosophy is quite the same as for lung metastasectomy. Local recurrences are possible and usually, whenever it is feasible, you could consider a new operation as an option. If you have done a lung-sparing resection, you will be able to perform another resection in the future.
Dr E. Vallières (Seatte, WA, USA): As you know, we have published and presented last year a series that concluded differently than yours. My question to you is: do you believe that biologically the peripheral, typical carcinoid tumour is different than a central airway, typical carcinoid tumour? Do you believe they are different?
Dr Filosso: I know the results of your paper that has been presented last year during the AATS Annual Meeting. I think that currently we have some biological tests, which seem to be able to differentiate neuroendocrine tumours' real biological behaviour. I mean, the NET test we are now using, in cooperation with Yale University. The first result of this liquid biopsy, confirm that it's able to predict tumour's biological behaviour its aggressiveness as well as possible recurrences development before their radiological demonstration. I don't know if, from a strict biological point of view, centrally located typical carcinoid may be different from peripheral one. However, I can tell you that the curves are showing a trend towards a worse survival in this case.
Dr Vallières: Personally, I don't believe they are very different. If you we can get away with a sleeve resection of the left main bronchus and put it back together with clean margins measured in mms and everything is good, you we should be able to get away with a wedge resection of a peripheral tumour if they are both biologically the same. That is my take on it.
